Search

Your search keyword '"Andrulli, S"' showing total 213 results
Start Over Author "Andrulli, S"
213 results on '"Andrulli, S"'

10. Sicurezza nella scelta dell'Inibitore di Pompa Protonica nel nefropatico cronico

Author

Sequenza, M. J., Loi, M.R., Londrino, F., Sale, P., Andrulli, S., Noce, A., Durante, O., Zamboli, P., Floccari, F., Fiorini, F., D’Amelio, A., di Lullo, Luca, Granata, A., Mudoni, A., Logias, F., Sequenza, M. J., Loi, M.R., Londrino, F., Sale, P., Andrulli, S., Noce, A., Durante, O., Zamboli, P., Floccari, F., Fiorini, F., D’Amelio, A., di Lullo, Luca, Granata, A., Mudoni, A., and Logias, F.

Abstract

Il paziente nefropatico cronico facilmente presenta alterazioni morfologiche e funzionali dell'apparato gastroenterico. I segni più comuni e precoci nella sindrome uremica cronica sono rappresentati dai disturbi gastrointestinali. Da alcuni decenni abbiamo a disposizione dei farmaci con potente azione inibente la secrezione acida gastrica: gli inibitori di pompa protonica (IPP) hanno una struttura chimica affine, uno stesso meccanismo d'azione e sono molto importanti per il trattamento delle patologie acido correlate, per l'eradicazione dell'Helicobacter Pylori, per la prevenzione e la cura della gastropatia da farmaci antinfiammatori non steroidei (FANS). Somministriamo ai nostri pazienti questa classe di farmaci, con terapie che continuano nel tempo, nonostante la risoluzione della malattia (gastroprotezione). Ma gli IPP possono essere utilizzati indistintamente nei nefropatici cronici oppure sarebbe utile conoscere il profilo del farmaco per una corretta scelta? In questo articolo si argomenta che i loro effetti collaterali non sono molto rilevanti e sono abbastanza simili: il loro impiego nel lungo termine è sicuro. La potenza e l'efficacia dei vari IPP, dall'analisi comparativa dei vari trial clinici, risulta essere molto simile sulla base dei milligrammi di sostanza utilizzata. L'unica eccezione illustrata in questo lavoro è rappresentata da 6 pazienti in emodialisi, trattati con lansoprazolo (15 mg), che presentavano gastriti e ulcere peptiche complicate da gravi episodi di ematemesi e melena con conseguente anemia. Tutti gli IPP hanno dimostrato un'efficacia clinica sovrapponibile, tuttavia vanno valutati di volta in volta i vantaggi (relativi) di ciascun IPP. I criteri di scelta di un IPP sembrano basati, principalmente sulle indicazioni autorizzate, sulle formulazioni disponibili, sul profilo di sicurezza del farmaco., Chronic nephropathic patients often present morphological and functional alterations of the gastro-enteric apparatus. Gastrointestinal diseases represent the most common and early signs. PPIs presented for many decades an important inhibitory effect on gastric acid secretion: they have a common chemical structure, a common mechanism of action and they are very important for treating acid-related pathologies, for Helicobacter Pylori eradication, for preventing and curing NSAIDs gastropathies. We prescribe this class of drugs to our patients even after the pathology resolution (gastroprotection). However can PPIs be indiscriminately used with chronic nephropathic patients or is it necessary to know the drug profile, in order to make a better choice? In this paper we argue that collateral effects are not very relevant and that they are very similar: their long-term usage is very safe. Power and efficacy of the different PPIs results very similar on the basis of how many milligrams of substance has been used and on the basis of clinical trials. The only exception that is shown in this paper is represented by 6 haemodialysis patients, which have been treated with lansoprazol (15 mgs). They presented gastritis and peptic ulcers, which were complicated by episodes of severe hematemesis and melena, with a consequent anaemia. Even though all PPIs have shown a similar clinical efficacy it is important to evaluate from time to time the (relative) advantages of each PPI. Criteria for a correct choice should be based mainly on official indications, on available doses and on the safety of the drug.

Published
2018

11. A rare case of renal ectopia

Author

D’Amelio, A., Lusenti, T., Granata, A., Andrulli, S., Fiorini, F., D’Amelio, A., Lusenti, T., Granata, A., Andrulli, S., and Fiorini, F.

Abstract

No abstract, non disponibile

Published
2018

12. A strange renal colic in a nephrolithic patient and ... not only

Author

Lusenti, T., Fiorini, F., D’Amelio, A., Granata, A., Andrulli, S., Lusenti, T., Fiorini, F., D’Amelio, A., Granata, A., and Andrulli, S.

Abstract

No abstract, Maschio di 56 anni con familiarità positiva per nefrolitiasi ed anamnesi positiva per numerosi episodi di colica renoureterale da ambo i lati, si presenta al nostro ambulatorio nefrologico di ecografia per ennesimo episodio recidivo di colica renale destra. All'ultimo controllo ecografico dei reni presentava microlitiasi bilaterale in assenza di dilatazione delle vie escretrici. È in terapia dietetico-idropinica associata a citrato di potassio. All'ecografia renale presenta idronefrosi del rene destro in assenza di idrouretere. La TAC, eseguita senza mezzo di contrasto per pregresso episodio di allergia al mdc in corso di precedente esame radiologico conferma la dilatazione delle vie escretrici a carico del rene destro. La successiva RMN dell'addome ribadisce l'idronefrosi destra riscontrata all'ecografia e alla TAC, sino alla giunzione pieloureterale con uretere a valle non dilatato che depongono per ostruzione del giunto pieloureterale (OGPU). Il paziente operato di plastica del giunto pieloureterale è al momento libero da coliche. Il caso riportato ribadisce come nei casi di idronefrosi accanto alle più comuni cause di uropatia ostruttiva (calcolosi, IPB, neoplasie) occorra sempre considerare le patologie congenite che possono manifestarsi anche in età adulta e tra queste in particolare la sindrome del giunto pieloureterale. In questi pazienti l'ecografia renale rappresenta un importante esame di primo livello in base alla quale indirizzare il paziente ai successivi step diagnostici di imaging e ai conseguenti provvedimenti terapeutici.

Published
2018

13. PPIs in Chronic Nephropatic Patient

Author

Sequenza, M. J., Loi, M.R., Londrino, F., Sale, P., Andrulli, S., Noce, A., Durante, O., Zamboli, P., Floccari, F., Fiorini, F., D’Amelio, A., di Lullo, Luca, Granata, A., Mudoni, A., Logias, F., Sequenza, M. J., Loi, M.R., Londrino, F., Sale, P., Andrulli, S., Noce, A., Durante, O., Zamboli, P., Floccari, F., Fiorini, F., D’Amelio, A., di Lullo, Luca, Granata, A., Mudoni, A., and Logias, F.

Abstract

Chronic nephropathic patients often present morphological and functional alterations of the gastro-enteric apparatus. Gastrointestinal diseases represent the most common and early signs. PPIs presented for many decades an important inhibitory effect on gastric acid secretion: they have a common chemical structure, a common mechanism of action and they are very important for treating acid-related pathologies, for Helicobacter Pylori eradication, for preventing and curing NSAIDs gastropathies. We prescribe this class of drugs to our patients even after the pathology resolution (gastroprotection). However can PPIs be indiscriminately used with chronic nephropathic patients or is it necessary to know the drug profile, in order to make a better choice? In this paper we argue that collateral effects are not very relevant and that they are very similar: their long-term usage is very safe. Power and efficacy of the different PPIs results very similar on the basis of how many milligrams of substance has been used and on the basis of clinical trials. The only exception that is shown in this paper is represented by 6 haemodialysis patients, which have been treated with lansoprazol (15 mgs). They presented gastritis and peptic ulcers, which were complicated by episodes of severe hematemesis and melena, with a consequent anaemia. Even though all PPIs have shown a similar clinical efficacy it is important to evaluate from time to time the (relative) advantages of each PPI. Criteria for a correct choice should be based mainly on official indications, on available doses and on the safety of the drug., Il paziente nefropatico cronico facilmente presenta alterazioni morfologiche e funzionali dell'apparato gastroenterico. I segni più comuni e precoci nella sindrome uremica cronica sono rappresentati dai disturbi gastrointestinali. Da alcuni decenni abbiamo a disposizione dei farmaci con potente azione inibente la secrezione acida gastrica: gli inibitori di pompa protonica (IPP) hanno una struttura chimica affine, uno stesso meccanismo d'azione e sono molto importanti per il trattamento delle patologie acido correlate, per l'eradicazione dell'Helicobacter Pylori, per la prevenzione e la cura della gastropatia da farmaci antinfiammatori non steroidei (FANS). Somministriamo ai nostri pazienti questa classe di farmaci, con terapie che continuano nel tempo, nonostante la risoluzione della malattia (gastroprotezione). Ma gli IPP possono essere utilizzati indistintamente nei nefropatici cronici oppure sarebbe utile conoscere il profilo del farmaco per una corretta scelta? In questo articolo si argomenta che i loro effetti collaterali non sono molto rilevanti e sono abbastanza simili: il loro impiego nel lungo termine è sicuro. La potenza e l'efficacia dei vari IPP, dall'analisi comparativa dei vari trial clinici, risulta essere molto simile sulla base dei milligrammi di sostanza utilizzata. L'unica eccezione illustrata in questo lavoro è rappresentata da 6 pazienti in emodialisi, trattati con lansoprazolo (15 mg), che presentavano gastriti e ulcere peptiche complicate da gravi episodi di ematemesi e melena con conseguente anemia. Tutti gli IPP hanno dimostrato un'efficacia clinica sovrapponibile, tuttavia vanno valutati di volta in volta i vantaggi (relativi) di ciascun IPP. I criteri di scelta di un IPP sembrano basati, principalmente sulle indicazioni autorizzate, sulle formulazioni disponibili, sul profilo di sicurezza del farmaco.

Published
2018

14. Primary and secondary prevention of arterial hypertension: nephrologist's point of view

Author

Andrulli, S., Mancuso, S., Bigi, M.C., Granata, A., Logias, F., Floccari, F., Di Lullo, L., Andrulli, S., Mancuso, S., Bigi, M.C., Granata, A., Logias, F., Floccari, F., and Di Lullo, L.

Abstract

Nephroangiosclerotic chronic kidney disease's primary and secondary prevention is actually based on blood pressure control and reduction of proteinuria. In proteinuric patients, blood pressure control has to be obtained by blocking renin–angiotensin axis, even in patients with moderate to severe chronic kidney disease. Combination therapy with angiotensin converting enzyme inhibitor (ACEi) drugs and angiotensin II receptor blockers (ARB) doesn't imply addictive protective effects. It could be tested in selected patients with proteinuria levels above 1 g/day. Combination therapy with ACEi and anti–aldosteronic agents seems to be promising but we need more multicentric trials., La prevenzione primaria e secondaria della insufficienza renale cronica da nefroangiosclerosi è rappresentata dallo stretto controllo dei valori pressori e dalla riduzione della proteinuria. In presenza di proteinuria, il controllo pressorio va ottenuto con il blocco del sistema renina-angiotensina anche in pazienti con importante riduzione della funzione renale. La terapia di associazione di ACE inibitore con sartano non sembra portare vantaggi aggiuntivi ma può essere saggiata in pazienti selezionati con proteinuria persistente superiore al grammo/die. L'associazione ACE inibitore con antialdosteronico sembra promettere bene ma occorrono ulteriori studi, possibilmente multicentrici.

Published
2018

15. Sicurezza nella scelta dell'Inibitore di Pompa Protonica nel nefropatico cronico

Author

Sequenza, M. J., primary, Loi, M.R., additional, Londrino, F., additional, Sale, P., additional, Andrulli, S., additional, Noce, A., additional, Durante, O., additional, Zamboli, P., additional, Floccari, F., additional, Fiorini, F., additional, D’Amelio, A., additional, Di Lullo, Luca, additional, Granata, A., additional, Mudoni, A., additional, and Logias, F., additional

Published
2018
Full Text
View/download PDF

19. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial

Author

Maritati, F, Alberici, F, Oliva, E, Urban, M, Palmisano, A, Santarsia, F, Andrulli, S, Pavone, L, Pesci, A, Grasselli, C, Santi, R, Tumiati, B, Manenti, L, Buzio, C, Vaglio, A, Vaglio, A., PESCI, ALBERTO, Maritati, F, Alberici, F, Oliva, E, Urban, M, Palmisano, A, Santarsia, F, Andrulli, S, Pavone, L, Pesci, A, Grasselli, C, Santi, R, Tumiati, B, Manenti, L, Buzio, C, Vaglio, A, Vaglio, A., and PESCI, ALBERTO

Abstract

Objectives:Â The treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is based on remission-induction and remission-maintenance. Methotrexate is a widely used immunosuppressant but only a few studies explored its role for maintenance in AAV. This trial investigated the efficacy and safety of methotrexate as maintenance therapy for AAV. Methods: In this single-centre, open-label, randomised trial we compared methotrexate and cyclophosphamide for maintenance in AAV. We enrolled patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), the latter with poor-prognosis factors and/or peripheral neuropathy. Remission was induced with cyclophosphamide. At remission, the patients were randomised to receive methotrexate or to continue with cyclophosphamide for 12 months; after treatment, they were followed for another 12 months. The primary end-point was relapse; secondary end-points included renal outcomes and treatment-related toxicity. Results: Of the 94 enrolled patients, 23 were excluded during remission-induction or did not achieve remission; the remaining 71 were randomised to cyclophosphamide (n = 33) or methotrexate (n = 38). Relapse frequencies at months 12 and 24 after randomisation were not different between the two groups (p = 1.00 and 1.00). Relapse-free survival was also comparable (log-rank test p = 0.99). No differences in relapses were detected between the two treatments when GPA+MPA and EGPA were analysed separately. There were no differences in eGFR at months 12 and 24; proteinuria declined significantly (from diagnosis to month 24) only in the cyclophosphamide group (p = 0.0007). No significant differences in adverse event frequencies were observed. Conclusions: MTX may be effective and safe for remission-maintenance in AAV. Trial registration: clinicaltrials.gov NCT00751517

Published
2017

20. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy

Author

Pozzi C Andrulli S Pani A Scaini P Del Vecchio L Fogazzi G Vogt B De Cristofaro V Allegri L

Abstract

The optimal treatment for IgA nephropathy (IgAN) remains unknown. Some patients respond to corticosteroids suggesting that more aggressive treatment may provide additional benefit. We performed a randomized multicenter controlled trial to determine whether adding azathioprine to steroids improves renal outcome. We randomly assigned 207 IgAN patients with creatinine =2.0 mg/dl and proteinuria =1.0 g/d to either (1) a 3 day pulse of methylprednisolone in months 1 3 and 5 in addition to both oral prednisone 0.5 mg/kg every other day and azathioprine 1.5 mg/kg per day for 6 months (n = 101 group 1) or (2) steroids alone on the same schedule (n = 106 group 2). The primary outcome was renal survival (time to 50 increase in plasma creatinine from baseline); secondary outcomes were changes in proteinuria over time and safety. After a median follow up of 4.9 years the primary endpoint occurred in 13 patients in group 1 (12.9 95 CI 7.5 to 20.9) and 12 patients in group 2 (11.3 CI 6.5 to 18.9) (P = 0.83). Five year cumulative renal survival was similar between groups (88 versus 89; P = 0.83). Multivariate Cox regression analysis revealed that female gender systolic BP number of antihypertensive drugs ACE inhibitor use and proteinuria during follow up predicted the risk of reaching the primary endpoint. Treatment significantly decreased proteinuria from 2.00 to 1.07 g/d during follow up (P < 0.001) on average with no difference between groups. Treatment related adverse events were more frequent among those receiving azathioprine. In summary adding low dose azathioprine to corticosteroids for 6 months does not provide additional benefit to patients with IgAN and may increase the risk for adverse events.

Published
2010

25. Assessment of central adrenal insufficiency in children and adolescents with Prader-Willi syndrome

Author

Corrias, A, Grugni, G, Crinò, A, Di Candia, S, Chiabotto, P, Cogliardi, A, Chiumello, G, De Medici, C, Spera, S, Gargantini, L, Iughetti, Lorenzo, Luce, A, Mariani, B, Ragusa, L, Salvatoni, A, Andrulli, S, Mussa, A, and Beccaria, L.

Subjects
Male, Adolescent, Hydrocortisone, Infant, Newborn, Infant, Adrenal Insufficiency, Adrenocorticotropic Hormone, Body Mass Index, Child, Child, Preschool, Cross-Sectional Studies, Female, Humans, Prader-Willi Syndrome, Regression Analysis, Endocrinology, Diabetes and Metabolism, Newborn, Diabetes and Metabolism, Endocrinology, Prader-Willi syndrome, Preschool, Central adrenal insufficiency
Abstract

A recent study evidenced by metyrapone test a central adrenal insufficiency (CAI) in 60% of Prader-Willi syndrome (PWS) children. These results were not confirmed in investigations with low [Low-Dose Tetracosactrin Stimulation Test (LDTST), 1 μg] or standard-dose tetracosactrin stimulation tests. We extended the research by LDTST in paediatric patients with PWS.Cross-sectional evaluation of adrenal stress response to LDTST in a PWS cohort of a tertiary care referral centre.Eighty-four children with PWS.Assessment of adrenal response by morning cortisol and ACTH dosage, and 1-μg tetracosactrin test. Response was considered appropriate when cortisol reached 500 nm; below this threshold, patients were submitted to a second test. Responses were correlated with the patients' clinical and molecular characteristics to assess genotype-phenotype correlation.Pathological cortisol peak responses to the LDTST were registered in 12 patients (14.3%) who had reduced basal (169.4 ± 83.3 nm) and stimulated (428.1 ± 69.6 nm) cortisol levels compared to patients with normal responses (367.1 ± 170.6 and 775.9 ± 191.3 nm, P0.001). Body mass index standard deviation score was negatively correlated with basal and peak cortisol levels (both P0.001), and the patients' ages (P0.001). In patients with deletion on chromosome 15, the cortisol peak was significantly lower than that in uniparental disomy (UPD) cases (P = 0.030). At multiple regression analysis, the predictors of peak response were basal cortisol, age, and UPD subclass (r(2) = 0.353, P0.001). Standard-dose (250 μg) tetracosactrin test confirmed CAI in 4/12 patients (4.8% of the cohort).Our results support the hypothesis that, albeit rare, CAI may be part of the PWS in childhood.

Published
2011

30. Phosphate levels in patients treated with low-flux haemodialysis, pre-dilution haemofiltration and haemodiafiltration: post hoc analysis of a multicentre, randomized and controlled trial

Author

Locatelli, F., primary, Altieri, P., additional, Andrulli, S., additional, Sau, G., additional, Bolasco, P., additional, Pedrini, L. A., additional, Basile, C., additional, David, S., additional, Gazzanelli, L., additional, Tampieri, G., additional, Isola, E., additional, Marzolla, O., additional, Memoli, B., additional, Ganadu, M., additional, Reina, E., additional, Bertoli, S., additional, Ferrara, R., additional, Casu, D., additional, Logias, F., additional, Tarchini, R., additional, Mattana, G., additional, Passaghe, M., additional, Fundoni, G., additional, Villa, G., additional, Di Iorio, B. R., additional, Pontoriero, G., additional, and Zoccali, C., additional

Published
2014
Full Text
View/download PDF

31. Nutrition / inflammation

Author

Wong, M. M. Y., primary, Thijssen, S., additional, Usvyat, L. A., additional, Kotanko, P., additional, Maddux, F. W., additional, Speer, T., additional, Rohrer, L., additional, Blyzszuk, P., additional, Krankel, N., additional, Zewinger, S., additional, Martin, T., additional, von Eckardstein, A., additional, Luscher, T., additional, Landmesser, U., additional, Fliser, D., additional, Prats, M., additional, Font, R., additional, Garcia, C., additional, Cabre, C., additional, Jariod, M., additional, Martinez Vea, A., additional, Costa, E., additional, Ribeiro, S., additional, do Sameiro-Faria, M., additional, Rocha-Pereira, P., additional, Kohlova, M., additional, Fernandes, J., additional, Reis, F., additional, Miranda, V., additional, Quintanilha, A., additional, Bronze-da-Rocha, E., additional, Belo, L., additional, Santos-Silva, A., additional, Nascimento, H., additional, Schepers, E., additional, Glorieux, G., additional, Van den Abeele, T., additional, Neirynck, N., additional, Vanholder, R., additional, Boelaert, J., additional, Liabeuf, S., additional, Massy, Z., additional, Kaynar, K., additional, Kural, B. V., additional, Ulusoy, S., additional, Cansiz, M., additional, Akcan, B., additional, Misir, N., additional, Yaman, S., additional, Kaya, N., additional, Dimas, G. G., additional, Iliadis, F. S., additional, Tegos, T. J., additional, Spiroglou, S. G., additional, Pitsalidis, C. G., additional, Karamouzis, I. M., additional, Didaggelos, T. P., additional, Adamidou, A. P., additional, Savopoulos, C. G., additional, Karamouzis, M. I., additional, Orologas, A. G., additional, Hatzitolios, A. I., additional, Grekas, D. M., additional, Flisinski, M., additional, Brymora, A., additional, Stefanska, A., additional, Strozecki, P., additional, Manitius, J., additional, Khalfina, T. N., additional, Maksudova, A. N., additional, Valeeva, I. K., additional, Bantis, C., additional, Kouri, N.-M., additional, Bamichas, G., additional, Stangou, M., additional, Tsantekidou, E., additional, Natse, T., additional, Fazio, M. R., additional, Basile, G., additional, Lucisano, S., additional, Montalto, G., additional, Valeria, C., additional, Donato, V., additional, Lupica, R., additional, Trimboli, D., additional, Aloisi, C., additional, Buemi, M., additional, Henze, A., additional, Raila, J., additional, Scholze, A., additional, Schweigert, F., additional, Tepel, M., additional, Nakamichi, R., additional, Prates, E., additional, Redublo Quinto, B. M., additional, Zanella, M. T., additional, Batista, M. C., additional, Masajtis-Zagajewska, A., additional, Kurnatowska, I., additional, Wajdlich, M., additional, Nowicki, M., additional, Mennini, F., additional, Russo, S., additional, Marcellusi, A., additional, Quintaliani, G., additional, Andrulli, S., additional, Chiavenna, C., additional, Bigi, M. C., additional, Tentori, F., additional, Crepaldi, M., additional, Corti, M. M., additional, Dell'Oro, C., additional, Bacchini, G., additional, Limardo, M., additional, Pontoriero, G., additional, Williams, C., additional, Abbas, S. R., additional, Zhu, F., additional, Flores-Gama, C., additional, Moskowitz, J., additional, Cartagena, C., additional, Carter, M., additional, Levin, N., additional, de Oliveira, R. B., additional, Okazaki, H., additional, Lenglet, A., additional, Desjardins, L., additional, Lemke, H.-D., additional, Valholder, R., additional, Choukroun, G., additional, and Massy, Z. A., additional

Published
2013
Full Text
View/download PDF

33. PPIs in Chronic Nephropatic Patient

Author

Sequenza, M. J., primary, Loi, M.R., additional, Londrino, F., additional, Sale, P., additional, Andrulli, S., additional, Noce, A., additional, Durante, O., additional, Zamboli, P., additional, Floccari, F., additional, Fiorini, F., additional, D'Amelio, A., additional, di Lullo, Luca, additional, Granata, A., additional, Mudoni, A., additional, and Logias, F., additional

Published
2012
Full Text
View/download PDF

34. Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial

Author

Locatelli, F., primary, Altieri, P., additional, Andrulli, S., additional, Sau, G., additional, Bolasco, P., additional, Pedrini, L. A., additional, Basile, C., additional, David, S., additional, Feriani, M., additional, Nebiolo, P. E., additional, Ferrara, R., additional, Casu, D., additional, Logias, F., additional, Tarchini, R., additional, Cadinu, F., additional, Passaghe, M., additional, Fundoni, G., additional, Villa, G., additional, Di Iorio, B. R., additional, and Zoccali, C., additional

Published
2012
Full Text
View/download PDF

35. Effect of a plasma sodium biofeedback system applied to HFR on the intradialytic cardiovascular stability. Results from a randomized controlled study

Author

Locatelli, F., primary, Stefoni, S., additional, Petitclerc, T., additional, Coli, L., additional, Di Filippo, S., additional, Andrulli, S., additional, Fumeron, C., additional, Frasca, G. M., additional, Sagripanti, S., additional, Savoldi, S., additional, Serra, A., additional, Stallone, C., additional, Aucella, F., additional, Gesuete, A., additional, Scarlatella, A., additional, Quarello, F., additional, Mesiano, P., additional, Ahrenholz, P., additional, Winkler, R., additional, Mandart, L., additional, Fort, J., additional, Tielemans, C., additional, and Navino, C., additional

Published
2012
Full Text
View/download PDF

36. Extracorporeal dialysis: techniques and adequacy

Author

Donadio, C., primary, Kanaki, A., additional, Martin-Gomez, A., additional, Garcia, S., additional, Palacios-Gomez, M., additional, Donadio, C., additional, Calia, D., additional, Colombini, E., additional, DI Francesco, F., additional, Ghimenti, S., additional, Onor, M., additional, Tognotti, D., additional, Fuoco, R., additional, Marka-Castro, E., additional, Torres Zamora, M. I., additional, Giron-Mino, J., additional, Jaime-Solis, M. A., additional, Arteaga, L. M., additional, Romero, H., additional, Akonur, A., additional, Leypoldt, K., additional, Asola, M., additional, Culleton, B., additional, Eloot, S., additional, Glorieux, G., additional, Nathalie, N., additional, Vanholder, R., additional, Perez de Jose, A., additional, Verdalles Guzman, U., additional, Abad Esttebanez, S., additional, Vega Martinez, A., additional, Barraca, D., additional, Yuste, C., additional, Bucalo, L., additional, Rincon, A., additional, Lopez-Gomez, J. M., additional, Bataille, P., additional, Celine, P., additional, Raymond, A., additional, Francois, G., additional, Herve, L., additional, Michel, D., additional, Jean Louis, R., additional, Zhu, F., additional, Kotanko, P., additional, Thijssen, S., additional, Levin, N. W., additional, Papamichail, N., additional, Bougiakli, M., additional, Gouva, C., additional, Antoniou, S., additional, Gianitsi, S., additional, Vlachopanou, A., additional, Chachalos, S., additional, Naka, K., additional, Kaarsavvidou, D., additional, Katopodis, K., additional, Michalis, L., additional, Sasaki, K., additional, Yasuda, K., additional, Yamato, M., additional, Surace, A., additional, Rovatti, P., additional, Steckiph, D., additional, Bandini, R., additional, Severi, S., additional, Dellacasa Bellingegni, A., additional, Santoro, A., additional, Arias, M., additional, Sentis, A., additional, Perez, N., additional, Fontsere, N., additional, Vera, M., additional, Rodriguez, N., additional, Arcal, C., additional, Ortega, N., additional, Uriza, F., additional, Cases, A., additional, Maduell, F., additional, Abbas, S. R., additional, Georgianos, P., additional, Sarafidis, P., additional, Nikolaidis, P., additional, Lasaridis, A., additional, Ahmed, A., additional, Kaoutar, H., additional, Mohammed, B., additional, Zouhir, O., additional, Balter, P., additional, Ginsberg, N., additional, Taylor, P., additional, Sullivan, T., additional, Usvyat, L. A., additional, Zabetakis, P., additional, Moissl, U., additional, Ferrario, M., additional, Garzotto, F., additional, Wabel, P., additional, Cruz, D., additional, Tetta, C., additional, Signorini, M. G., additional, Cerutti, S., additional, Brendolan, A., additional, Ronco, C., additional, Heaf, J., additional, Axelsen, M., additional, Pedersen, R. S., additional, Amine, H., additional, Oualim, Z., additional, Ammirati, A. L., additional, Guimaraes de Souza, N. K., additional, Nemoto Matsui, T., additional, Luiz Vieira, M., additional, Alves de Oliveira, W. A., additional, Fischer, C. H., additional, Dias Carneiro, F., additional, Iizuka, I. J., additional, Aparecida de Souza, M., additional, Mallet, A. C., additional, Cruz Andreoli, M. C., additional, Cardoso Dos Santos, B. F., additional, Rosales, L., additional, Dou, Y., additional, Carter, M., additional, Testa, A., additional, Sottini, L., additional, Giacon, B., additional, Prati, E., additional, Loschiavo, C., additional, Brognoli, M., additional, Marseglia, C., additional, Tommasi, A., additional, Sereni, L., additional, Palladino, G., additional, Bove, S., additional, Bosticardo, G., additional, Schillaci, E., additional, Detoma, P., additional, Bergia, R., additional, Park, J. W., additional, Moon, S. J., additional, Choi, H. Y., additional, Ha, S. K., additional, Park, H.-C., additional, Liao, Y., additional, Zhang, L., additional, Fu, P., additional, Igarashi, H., additional, Suzuki, N., additional, Esashi, S., additional, Masakane, I., additional, Panichi, V., additional, De Ferrari, G., additional, Saffiotti, S., additional, Sidoti, A., additional, Biagioli, M., additional, Bianchi, S., additional, Imperiali, P., additional, Gabrielli, C., additional, Conti, P., additional, Patrone, P., additional, Rombola, G., additional, Falqui, V., additional, Mura, C., additional, Icardi, A., additional, Rosati, A., additional, Santori, F., additional, Mannarino, A., additional, Bertucci, A., additional, Jeong, J., additional, Kim, O. K., additional, Kim, N. H., additional, Bots, M., additional, Den Hoedt, C., additional, Grooteman, M. P., additional, Van der Weerd, N. C., additional, Mazairac, A. H. A., additional, Levesque, R., additional, Ter Wee, P. M., additional, Nube, M. J., additional, Blankestijn, P., additional, Van den Dorpel, M. A., additional, Park, Y., additional, Jeon, J., additional, Tessitore, N., additional, Bedogna, V., additional, Girelli, D., additional, Corazza, L., additional, Jacky, P., additional, Guillaume, Q., additional, Julien, B., additional, Marcinkowski, W., additional, Drozdz, M., additional, Milkowski, A., additional, Rydzynska, T., additional, Prystacki, T., additional, August, R., additional, Benedyk-Lorens, E., additional, Bladek, K., additional, Cina, J., additional, Janiszewska, G., additional, Kaczmarek, A., additional, Lewinska, T., additional, Mendel, M., additional, Paszkot, M., additional, Trafidlo, E., additional, Trzciniecka-Kloczkowska, M., additional, Vasilevsky, A., additional, Konoplev, G., additional, Lopatenko, O., additional, Komashnya, A., additional, Visnevsky, K., additional, Gerasimchuk, R., additional, Neivelt, I., additional, Frorip, A., additional, Vostry, M., additional, Racek, J., additional, Rajdl, D., additional, Eiselt, J., additional, Malanova, L., additional, Pechter, U., additional, Selart, A., additional, Ots-Rosenberg, M., additional, Krieter, D. H., additional, Seidel, S., additional, Merget, K., additional, Lemke, H.-D., additional, Wanner, C., additional, Canaud, B., additional, Rodriguez, A., additional, Morgenroth, A., additional, Von Appen, K., additional, Dragoun, G.-P., additional, Fluck, R., additional, Fouque, D., additional, Lockridge, R., additional, Motomiya, Y., additional, Uji, Y., additional, Hiramatsu, T., additional, Ando, Y., additional, Furuta, M., additional, Kuragano, T., additional, Kida, A., additional, Yahiro, M., additional, Otaki, Y., additional, Hasuike, Y., additional, Nonoguchi, H., additional, Nakanishi, T., additional, Sain, M., additional, Kovacic, V., additional, Ljutic, D., additional, Radic, J., additional, Jelicic, I., additional, Yalin, S. F., additional, Trabulus, S., additional, Yalin, A. S., additional, Altiparmak, M. R., additional, Serdengecti, K., additional, Ohtsuka, A., additional, Fukami, K., additional, Ishikawa, K., additional, Ando, R., additional, Kaida, Y., additional, Adachi, T., additional, Sugi, K., additional, Okuda, S., additional, Nesterova, O. B., additional, Suglobova, E. D., additional, Golubev, R. V., additional, Vasiliev, A. N., additional, Lazeba, V. A., additional, Smirnov, A. V., additional, Arita, K., additional, Kihara, E., additional, Maeda, K., additional, Oda, H., additional, Doi, S., additional, Masaki, T., additional, Hidaka, S., additional, Ishioka, K., additional, Oka, M., additional, Moriya, H., additional, Ohtake, T., additional, Nomura, S., additional, Kobayashi, S., additional, Wagner, S., additional, Gmerek, A., additional, Wagner, J., additional, Wizemann, V., additional, Eftimovska - Otovic, N., additional, Spaseska-Gjurovska, K., additional, Bogdanovska, S., additional, Babalj - Banskolieva, E., additional, Milovanceva, M., additional, Grozdanovski, R., additional, Pisani, A., additional, Riccio, E., additional, Mancini, A., additional, Ambuhl, P., additional, Astrid, S., additional, Ivana, P., additional, Martin, H., additional, Thomas, K., additional, Hans-Rudolf, R., additional, Daniel, A., additional, Denes, K., additional, Marco, M., additional, Wuthrich, R. P., additional, Andreas, S., additional, Andrulli, S., additional, Altieri, P., additional, Sau, G., additional, Bolasco, P., additional, Pedrini, L. A., additional, Basile, C., additional, David, S., additional, Feriani, M., additional, Nebiolo, P. E., additional, Ferrara, R., additional, Casu, D., additional, Logias, F., additional, Tarchini, R., additional, Cadinu, F., additional, Passaghe, M., additional, Fundoni, G., additional, Villa, G., additional, DI Iorio, B. R., additional, Zoccali, C., additional, Locatelli, F., additional, Hamamoto, M., additional, Lee, D.-Y., additional, Kim, B., additional, Moon, K. H., additional, LI, Z., additional, Ahrenholz, P., additional, Winkler, R. E., additional, Waitz, G., additional, Wolf, H., additional, Grundstrom, G., additional, Alquist, M., additional, Holmquist, M., additional, Christensson, A., additional, Bjork, P., additional, Abdgawad, M., additional, Ekholm, L., additional, Segelmark, M., additional, Corsi, C., additional, De Bie, J., additional, Mambelli, E., additional, Mortara, D., additional, Arroyo, D., additional, Panizo, N., additional, Quiroga, B., additional, Reque, J., additional, Melero, R., additional, Rodriguez-Ferrero, M., additional, Rodriguez-Benitez, P., additional, Anaya, F., additional, Luno, J., additional, Ragon, A., additional, James, A., additional, Brunet, P., additional, Ribeiro, S., additional, Faria, M. S., additional, Rocha, S., additional, Rodrigues, S., additional, Catarino, C., additional, Reis, F., additional, Nascimento, H., additional, Fernandes, J., additional, Miranda, V., additional, Quintanilha, A., additional, Belo, L., additional, Costa, E., additional, Santos-Silva, A., additional, Arund, J., additional, Tanner, R., additional, Fridolin, I., additional, Luman, M., additional, Clajus, C., additional, Kielstein, J. T., additional, Haller, H., additional, Libutti, P., additional, Lisi, P., additional, Vernaglione, L., additional, Casucci, F., additional, Losurdo, N., additional, Teutonico, A., additional, Lomonte, C., additional, Krisp, C., additional, Wolters, D. A., additional, Matsuyama, M., additional, Tomo, T., additional, Ishida, K., additional, Matsuyama, K., additional, Nakata, T., additional, Kadota, J., additional, Caiazzo, M., additional, Monari, E., additional, Cuoghi, A., additional, Bellei, E., additional, Bergamini, S., additional, Tomasi, A., additional, Baranger, T., additional, Seniuta, P., additional, Berge, F., additional, Drouillat, V., additional, Frangie, C., additional, Rosier, E., additional, Labonia, W., additional, Lescano, A., additional, Rubio, D., additional, Von der Lippe, N., additional, Jorgensen, J. A., additional, Osthus, T. B., additional, Waldum, B., additional, Os, I., additional, Bossola, M., additional, DI Stasio, E., additional, Antocicco, M., additional, Tazza, L., additional, Griveas, I., additional, Karameris, A., additional, Pasadakis, P., additional, Savica, V., additional, Santoro, D., additional, Saitta, S., additional, Tigano, V., additional, Bellinghieri, G., additional, Gangemi, S., additional, Daniela, R., additional, Checherita, I. A., additional, Ciocalteu, A., additional, Vacaroiu, I. A., additional, Niculae, A., additional, Stefaniak, E., additional, Pietrzak, I., additional, Krupa, D., additional, Garred, L., additional, Mancini, E., additional, Corrazza, L., additional, Atti, M., additional, Afsar, B., additional, Stamopoulos, D., additional, Mpakirtzi, N., additional, Gogola, B., additional, Zeibekis, M., additional, Stivarou, D., additional, Panagiotou, M., additional, Grapsa, E., additional, Vega Vega, O., additional, Barraca Nunez, D., additional, Fernandez-Lucas, M., additional, Gomis, A., additional, Teruel, J. L., additional, Elias, S., additional, Quereda, C., additional, Hignell, L., additional, Humphrey, S., additional, Pacy, N., additional, and Afentakis, N., additional

Published
2012
Full Text
View/download PDF

39. Reply

Author

Andrulli, S., primary, Turrin, A., additional, and Bigi, M. C., additional

Published
2010
Full Text
View/download PDF

45. Reply

Author

Locatelli, F., primary, Pozzi, C., additional, and Andrulli, S., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results